← Every insider
Paul A Mahon
EVP & GENERAL COUNSEL. Files against UTHR. Everything below is filed with the SEC within two business days of the trade. Filed as MAHON PAUL A.
Filed lines
66
2026-07-02 to 2026-09-17
Bought
—
open market
Sold
$25.8M
open market
Net
$25.8M
sold more
Every reported line
Purchases, sales, grants, option exercises and shares withheld for tax.
| Company | Action | Value |
|---|---|---|
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $696.6K |
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $1.4M |
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $420.4K |
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $579.7K |
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $62.6K |
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $160.5K |
| UTHRUnited Therapeutics Corp2026-09-17 | Option exercisederivative10b5-1 plan | — |
| UTHRUnited Therapeutics Corp2026-09-17 | Sale10b5-1 plan | $783.1K |
| UTHRUnited Therapeutics Corp2026-09-17 | Option exercise10b5-1 plan | $1.2M |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $1.1M |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $505K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $77.2K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $157.1K |
| UTHRUnited Therapeutics Corp2026-09-03 | Option exercisederivative10b5-1 plan | — |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $96.8K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $462.8K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $290.9K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $82.4K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $4.9K |
| UTHRUnited Therapeutics Corp2026-09-03 | Option exercise10b5-1 plan | $1.2M |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $740K |
| UTHRUnited Therapeutics Corp2026-09-03 | Sale10b5-1 plan | $449K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $261.1K |
| UTHRUnited Therapeutics Corp2026-08-20 | Option exercise10b5-1 plan | $392.8K |
| UTHRUnited Therapeutics Corp2026-08-20 | Option exercise10b5-1 plan | $819.2K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $1.4M |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $947.8K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $410.8K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $444.4K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $100.5K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $493.7K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $210.6K |
| UTHRUnited Therapeutics Corp2026-08-20 | Sale10b5-1 plan | $63.3K |
| UTHRUnited Therapeutics Corp2026-08-20 | Option exercisederivative10b5-1 plan | — |
| UTHRUnited Therapeutics Corp2026-08-20 | Option exercisederivative10b5-1 plan | — |
| UTHRUnited Therapeutics Corp2026-08-06 | Option exercise10b5-1 plan | $1.2M |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $389.8K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $924.1K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $701.7K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $835.9K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $404K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $186.8K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $682.1K |
| UTHRUnited Therapeutics Corp2026-08-06 | Sale10b5-1 plan | $167.2K |
| UTHRUnited Therapeutics Corp2026-08-06 | Option exercisederivative10b5-1 plan | — |
| UTHRUnited Therapeutics Corp2026-07-16 | Option exercise10b5-1 plan | $1.2M |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $316.6K |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $63.6K |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $458K |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $426.4K |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $1.8M |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $557.9K |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $812.6K |
| UTHRUnited Therapeutics Corp2026-07-16 | Sale10b5-1 plan | $42.9K |
| UTHRUnited Therapeutics Corp2026-07-16 | Option exercisederivative10b5-1 plan | — |
| UTHRUnited Therapeutics Corp2026-07-02 | Option exercise10b5-1 plan | $1.2M |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $360.6K |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $141.6K |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $211.2K |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $808.8K |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $1M |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $1.2M |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $165.8K |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $550.3K |
| UTHRUnited Therapeutics Corp2026-07-02 | Sale10b5-1 plan | $125.2K |
| UTHRUnited Therapeutics Corp2026-07-02 | Option exercisederivative10b5-1 plan | — |
Source: SEC Form 4 and Form 144 filings, via EDGAR. Form 144 carries no filer identifier, so those notices are matched to this page by name alone. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
Follow Paul A Mahon by email
Paul A Mahon's new Form 4 trades, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.